Atrial Fibrillation: Should We Screen All to Reduce Stroke?
Is it time for universal screening for atrial fibrillation (AF), the most commonly treated type of arrhythmia that sets people up for strokes?
The question is important. While estimates of prevalence vary, a recent study found AF affects about 4% of the adult population or about 10 million in the United States. More than 795,000 people in the United States have a stroke each year, and AF is blamed for 1 in 7.
For now, however, US organizations that issue guidelines and many leading cardiologists agree: It's not yet warranted and may result in anticoagulation overtreatment, along with what they call the 'nontrivial' risk for bleeding from that treatment.
However, it's definitely a stay tuned situation, as researchers continue to investigate whether widespread screening can reduce the number of strokes in the broad population, others look at the role of 'smart' technology, and still others focus on subsets of the population that might benefit most from routine screening.
One widely anticipated study is the Heartline Study, a collaboration between Johnson & Johnson and Apple, with researchers analyzing the impact of an app-based heart health program done with the Apple watch on the early detection of irregular heart rhythms consistent with AF and how detection might reduce stroke risk. The trial has concluded, with results expected soon.
Current Guidelines
Meanwhile, two leading US organizations that issued recent guidelines do not favor universal screening for AF.
In 2022, the United States Preventive Services Task Force (USPSTF) guideline concluded that for asymptomatic adults aged 50 years or older, 'the current evidence is insufficient to assess the balance of benefits and harms of screening for atrial fibrillation.' The guideline updated the 2018 guideline, which assessed the evidence for detecting AF using ECG. The updated guideline also looked at other screening tests, still concluding the evidence was inadequate. Besides ECG use, AF may be detected using ambulatory blood pressure monitors, pulse oximeters or wearables, as well as pulse palpitation and heart auscultation.
In joint guidelines released in November 2023, the American Heart Association and American College of Cardiology concluded that for risk stratification models and screening programs to be useful, 'they would need to improve outcomes and be cost-effective,' noting that evidence is not established to prove those at a high risk for AF by a validated risk score benefit from screening and intervention to improve stroke rates, embolism rates, and survival.
Cardiologist: Currently Little Interest in Universal Screening
'To be honest with you, I don't think many in cardiology are interested in doing universal screening,' said Peter Zimetbaum, MD, associate chief and clinical director of Cardiology at Beth Israel Deaconess Medical Center and Smith professor of medicine at Harvard Medical School, Boston. After the USPSTF guidelines were issued in 2018, Annals of Internal Medicine published an invited point-counterpoint, with Zimetbaum presenting the viewpoint against routine screening.
Peter Zimetbaum, MD
He wrote: 'Atrial fibrillation is often asymptomatic and paroxysmal, and studies of episodic vs continuous monitoring have demonstrated that the more thoroughly one looks, the more AF will be found.'
The potential downside, he noted, is the unintended consequence of initiating lifelong anticoagulation treatment in patients who may not need it, including the potential risk for bleeding and negative impact on quality of life, which 'should not be minimized,' he said.
He does recommend screening in some, such as patients with a history of embolic stroke of uncertain source.
Taking the pro side in favor of screening, Steven Lubitz, MD, then at Massachusetts General Hospital, Boston, reasoned that AF may be asymptomatic and that subclinical AF is a known risk factor for stroke. He noted the various methods that can be used, including pulse monitoring and electrocardiology. Physicians are already screening for AF with pulse palpation and cardiac auscultation, Lubitz pointed out. The question is whether adding ECG is more effective than the standard of care.
Keeping an Open Mind
The question of routine screening is understandably an area of research interest, Zimetbaum said, as a significant percentage of patients present for the first time with AF when they have had a stroke, and ongoing advances in technology have made it easier to identify AF. The widespread adoption of wearable technologies such as smartwatches is also picking up AF in patients, he said.
Even so, he said, 'the reason why the organizations have come out not in favor of widespread screening is there is not enough evidence to demonstrate we can reduce strokes by identifying AF in the broadscale population.'
Many patients will come in to see him, Zimetbaum said, after they have AF picked up on their pacemaker, wanting to talk about the merits of anticoagulation treatment.
'I also get a lot of patients referred to me because they have a wearable of some sort that has alerted them that they have atrial fibrillation.' Of the wearables, he said 'they are reasonably accurate but not very accurate.'
Since 2019, when he wrote the counterpoint, 'my opinion has not changed.'
However, he is keeping an open mind. He said he expects wearables to improve and sees improving the accurate identification of AF as a goal worthy of more study.
Research Focus: Episode Duration, Risk Factors
Since the 2022 guidelines were issued, 'we do not have explosive new data to conclude this debate,' said Rod Passman, MD, MSCE, professor of medicine and preventive medicine at Northwestern University Feinberg School of Medicine in Chicago and director of the university's Center for Arrhythmia Research.
Rod Passman, MD, MSCE
However, 'the ARTESIA trial published in 2024 found a reduction in stroke risk when treating patients with anticoagulation who had short episodes of AF detected on their pacemaker or ICD [implantable cardioverter-defibrillators] who also had other stroke risk factors.'
But whether the same can be said for those with AF detected by other screening methods is not yet known, Passman said.
'There is no consensus on how much AF is too much,' Passman told Medscape Medical News . 'Most would agree that one or more episodes over 24 hours may benefit from anticoagulation if multiple other stroke risk factors are present; there is less consensus of opinion on episodes shorter than that.'
In a previous study, Passman and his colleagues found that a combination of AF duration and underlying risk factors increases stroke risk. 'AF episodes in someone with no or one risk factor may not increase stroke risk, but the more risk factors you have, the shorter the AF episodes associated with stroke.'
In his view, 'When we discuss screening, therefore, it is important to recognize that we should be screening those with an elevated risk of having the disease plus other risk factors that would dictate treatment should the disease be present.'
The Promise of Wearables
'Patients come to me every week because their watch told them they have AF,' Passman said. 'So using these technologies as a screening tool makes intuitive sense but has not yet been sufficiently proven to reduce hard endpoints such as stroke, in my opinion.'
Zachary Goldberger, MD, MS, a cardiologist and professor of medicine at the University of Wisconsin-Madison School of Medicine and Public Health, told Medscape Medical News : 'I think photoplethysmography can be a very powerful screening tool, but there are clear challenges. One is the amount of data we are going to receive, and already are receiving, and how much of that is interpretable and actionable.'
His hope: 'We really need to find a better means of identifying who we should target these wearables toward.' He added: 'It can't be ignored that this technology is not always affordable.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
5 Surprising Special Services Medicare Still Covers
Many retirees think of Medicare when it comes to covering hospital visits and doctor's appointments. However, Medicare still offers support for a range of special services. From Botox to in-home support, these benefits can make a significant difference in quality of life, especially as healthcare costs continue to rise. Be Aware: Find Out: Here are five surprising special services Medicare still covers. Also see two important Medicare issues that Suze Orman wants you to understand. While Botox is widely known for cosmetic use, Medicare may cover it when prescribed as a medically necessary treatment. 'It's specifically approved for certain medical conditions,' said Kiara DeWitt, RN, CPN, founder and CEO of Injectco. 'Chronic migraine is the main one, but other neurological disorders like cervical dystonia (a painful neck muscle condition), and blepharospasm count too.' DeWitt explained that the catch is Botox isn't covered for cosmetic use, so patients have to meet the clinical criteria. For example, Botox injections are sometimes approved for managing an overactive bladder or severe underarm sweating when other treatments have failed. 'You still need a provider who accepts Medicare and can submit the paperwork right,' DeWitt said. 'Otherwise, you are paying hundreds per treatment when you technically qualify. The system will not advertise this, but it is buried in there. You just need a diagnosis that fits and a provider who knows how to code it.' Read Next: Original Medicare (Parts A and B) typically doesn't include dental care. However, that doesn't mean enrollees are out of options. Many are surprised to learn that certain dental services are covered under specific circumstances. While routine dental care like cleanings and fillings isn't covered under traditional Medicare, Part A may cover dental work if it's part of a hospital-related procedure, such as jaw reconstruction after an injury or surgery that requires dental clearance. 'Medicare beneficiaries often are unaware that dental is included in Medicare Advantage Plans (Part C),' said Eric Salinas, a licensed health insurance agent at El-Mag Insurance. For broader coverage, many Medicare Advantage (Part C) plans offer dental benefits that include exams, X-rays, cleanings and even dentures. These benefits vary by plan and location, so it's worth reviewing available options during open enrollment to avoid paying out of pocket for essential oral healthcare. Many beneficiaries are surprised to discover that Medicare still covers a range of home-based and mental health services under certain conditions. From chronic care management, transitional care and telehealth counseling to the innovative GUIDE Model for dementia support, these benefits offer critical assistance for patients and caregivers. 'One of the most exciting developments is CMS's (Centers for Medicare & Medicaid Services) GUIDE Model,' said Jared Laudie, owner of Visiting Angels. 'It's a new dementia care initiative that funds services like caregiver training, respite care and 24/7 care navigation for families managing Alzheimer's or other dementias.' However, the services are subject to specific eligibility criteria. 'In-home medical care usually requires that the individual be homebound and under a physician's care,' Laudie said. 'Counseling often requires a diagnosis and provider referral.' And be sure to know all of the requirements to make sure you qualify. 'With the GUIDE Model, participation is limited to providers enrolled in the program, and patients must have a formal dementia diagnosis. Many people miss out simply because they don't know what to ask for or which providers participate.' One lesser-known Medicare benefit is its coverage of speech-generating devices for individuals with conditions like ALS or advanced Parkinson's disease that result in severe speech impairments. These devices can be life-changing, allowing patients to communicate more effectively with caregivers and loved ones. 'But access depends on proper clinical documentation, including a formal evaluation by a qualified speech-language pathologist,' said Dr. Kimberly Idoko, a board-certified neurologist and medical director at Everwell Neuro. For Medicare beneficiaries living with two or more chronic conditions, chronic special needs plans (C-SNPs) offer a tailored alternative that many overlook. 'For those eligible, these plans can provide additional benefits and resources not usually covered by Original Medicare or other Medicare Advantage plans,' said Whitney Stidom, vice president of Medicare enablement at eHealth. 'For instance, some C-SNPs may provide additional resources for people with diabetes, including improved coverage for blood glucose monitoring supplies or access to lifestyle programs focused on improving nutrition and exercise habits. This can help people save on out-of-pocket costs to help treat their condition, while empowering them to adopt a healthier lifestyle.' More From GOBankingRates 3 Luxury SUVs That Will Have Massive Price Drops in Summer 2025 8 Common Mistakes Retirees Make With Their Social Security Checks 4 Affordable Car Brands You Won't Regret Buying in 2025 This article originally appeared on 5 Surprising Special Services Medicare Still Covers
Yahoo
an hour ago
- Yahoo
Extreme heat safety tips as dangerous temperatures head to East Coast
Life-threatening heat is enveloping the eastern U.S., with some cities bracing for what could be their highest temperatures in over a decade. On Monday, the heat index -- what the temperature feels like with humidity -- is expected to skyrocket to 98 degrees in New York City; 107 degrees in Philadelphia; 109 degrees in Richmond, Virginia; and 106 in Raleigh, North Carolina, and Charleston, West Virginia. Temperatures are forecast to be slightly higher on Tuesday. Doctors recommend taking excessive heat warnings seriously. Over 700 people die from heat-related illnesses every year, according to the Centers for Disease Control and Prevention, and extreme heat is considered the deadliest weather-related hazard in the U.S., according to the Fifth National Climate Assessment. A heat wave is a continuous period of abnormally hot weather, generally lasting over two days, according to the National Weather Service. However, the definition of a heat wave varies by region. MORE: How to conserve energy during a heat wave In the Midwest and the Northeast, a heat wave is considered three or more days in a row of temperatures of at least 90 degrees. But in Phoenix, for example, temperatures are regularly well above 90 degrees and into the triple digits without it being from a heat wave. So a heat wave is relative to the local average temperature and may require temperatures to be significantly above normal for several days, according to the NWS. Here are tips to stay safe from the heat from the CDC: Take precautions to prevent sunburn, which can make you dehydrated and affect your ability to cool down. Use sunscreen that's SPF 15 or higher 30 minutes before going outside. Sunscreens that say "broad spectrum" or "UVA/UVB protection" are best. Drink extra fluids, and don't wait until you're thirsty. Avoid very sugary drinks and alcohol, which can cause your body to lose more fluid, and be wary of extra-cold drinks that may cause stomach cramps. Avoiding hot and heavy meals also can reduce your body's overall temperature. Cut down on exercise during heat waves and rest often and in shady areas. Try to limit your time outside to when it is cooler, like in the early morning and evening. Never leave children in a parked car -- even if windows are cracked open. MORE: Hot car safety tips Anyone can suffer from heat-related illness at any time, but these people are at greater risk: -- Babies and young children -- Overweight people -- Those 65 years old or older -- People who overexert during work or exercise -- Those who suffer from heart disease or high blood pressure and those who take certain medications, including for depression, insomnia or poor circulation Symptoms of heat stroke include: -- Body temperature of 103 degrees or higher -- Hot, red, dry or damp skin -- Fast, strong pulse -- Headache -- Dizziness -- Nausea -- Confusion -- Passing out -- No longer sweating Symptoms of heat exhaustion include: -- Heavy sweating -- Cold, pale, clammy skin -- Fast, weak pulse -- Nausea or vomiting -- Muscle cramps -- Feeling tired or weak -- Headache -- Passing out If someone shows symptoms of heat stroke or heat exhaustion, call 911, move them somewhere cooler and use towels to cool down their body. Don't forget about your furry friends! Here are some tips from the American Society for the Prevention of Cruelty to Animals for how to keep your pets safe in the heat: provide plenty of fresh water so they don't get dehydrated; don't over-exercise pets; never leave pets alone in a parked car; and watch for symptoms of overheating, which include excessive panting, difficulty breathing, increased heart and respiratory rate and drooling. Animals with flat faces, like pugs, can't pant as well and are more at risk of heat stroke. These pets, as well as older and overweight pets, should be kept inside as much as possible. ABC News' Kyle Reiman contributed to this report.
Yahoo
an hour ago
- Yahoo
Novo Nordisk terminates collaboration with Hims & Hers Health, Inc. due to concerns about their illegal mass compounding and deceptive marketing
Collaboration of over one month has ended based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk Novo Nordisk won't stop taking action to protect Americans from the dangers of illicit foreign active pharmaceutical ingredients in knock-off drugs Efforts will continue to make authentic, FDA-approved Wegovy® directly available through NovoCare® Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients living with chronic diseases PLAINSBORO, N.J., June 23, 2025 /PRNewswire/ -- Novo Nordisk announced today that the company will no longer be working with Hims & Hers Health, Inc., and that direct access to Wegovy® will no longer be available to Hims & Hers Health, Inc. via NovoCare® Pharmacy. In late April, the FDA resolved the Wegovy® shortage based on its conclusion that Novo Nordisk is fully meeting current and projected nationwide demand for this medicine. In support of transitioning patients from knock-off compounded versions to authentic, FDA-approved Wegovy® through NovoCare® Pharmacy, Novo Nordisk began collaborating with telehealth companies. Over one month into the collaboration, Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of "personalization" and are disseminating deceptive marketing that put patient safety at risk. "Novo Nordisk is firm on our position and protecting patients living with obesity. When patients are prescribed semaglutide treatments by their licensed healthcare professional or a telehealth provider, they are entitled to receive authentic, FDA-approved and regulated Wegovy®," said Dave Moore, Executive Vice President, US Operations of Novo Nordisk Inc. "We will work with telehealth companies to provide direct access to Wegovy® that share our commitment to patient safety – and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." Novo Nordisk is deeply concerned and is continuing to take proactive measures to keep US patients safe from knock-off drugs made with foreign illicit active pharmaceutical ingredients. Based on Novo Nordisk's investigation, the "semaglutide" active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies are manufactured by foreign suppliers in China. According to a report from the Brookings Institute, FDA has never authorized or approved the manufacturing processes used by any of these foreign suppliers to make semaglutide, nor has FDA ever reviewed or authorized the quality of the "semaglutide" they produce. The report also found that a "large share of [these Chinese suppliers] were never inspected by FDA, and many of those that were [inspected] had drug quality assurance violations." US patients should not be exposed to knock-off drugs made with unsafe and illicit foreign ingredients. More information can be found on About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.1-3 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.2,3 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.4,5 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.6,7 In the US, about 40% of adults live with obesity.8 About NovoCare® Pharmacy NovoCare® Pharmacy provides cash-paying patients who have been prescribed Wegovy® with the ability to schedule shipments of their Wegovy® prescriptions directly to their home. Beyond convenient home delivery, NovoCare® also supports patients with benefit verification, refill reminders, and access to live support from a NovoCare® case manager. More information about NovoCare® Pharmacy is available at NovoCare® pharmacy | NovoCare®. About Wegovy® (semaglutide) injection 2.4 mg What is Wegovy®? WEGOVY® (semaglutide) injection 2.4 mg is an injectable prescription medicine used with a reduced calorie diet and increased physical activity: to reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight. that may help adults and children aged 12 years and older with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off. Wegovy® contains semaglutide and should not be used with other semaglutide-containing products or other GLP-1 receptor agonist medicines. It is not known if Wegovy® is safe and effective for use in children under 12 years of age. Important Safety Information What is the most important information I should know about Wegovy®? Wegovy® may cause serious side effects, including: Possible thyroid tumors, including cancer. Tell your healthcare provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath. These may be symptoms of thyroid cancer. In studies with rodents, Wegovy® and medicines that work like Wegovy® caused thyroid tumors, including thyroid cancer. It is not known if Wegovy® will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in people Do not use Wegovy® if you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Do not use Wegovy® if: you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy® Before using Wegovy®, tell your healthcare provider if you have any other medical conditions, including if you: have or have had problems with your pancreas or kidneys have type 2 diabetes and a history of diabetic retinopathy have or have had depression, suicidal thoughts, or mental health issues are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation) are pregnant or plan to become pregnant. Wegovy® may harm your unborn baby. You should stop using Wegovy® 2 months before you plan to become pregnant are breastfeeding or plan to breastfeed. It is not known if Wegovy® passes into your breast milk Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Wegovy® may affect the way some medicines work and some medicines may affect the way Wegovy® works. Tell your healthcare provider if you are taking other medicines to treat diabetes, including sulfonylureas or insulin. Wegovy® slows stomach emptying and can affect medicines that need to pass through the stomach quickly. What are the possible side effects of Wegovy®? Wegovy® may cause serious side effects, including: inflammation of your pancreas (pancreatitis). Stop using Wegovy® and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without vomiting. You may feel the pain from your abdomen to your back gallbladder problems. Wegovy® may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stools increased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas. This can be a serious side effect. Talk to your healthcare provider about how to recognize and treat low blood sugar and check your blood sugar before you start and while you take Wegovy®. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jittery kidney problems (kidney failure). In people who have kidney problems, diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems to get worse. It is important for you to drink fluids to help reduce your chance of dehydration severe stomach problems. Stomach problems, sometimes severe, have been reported in people who use Wegovy®. Tell your healthcare provider if you have stomach problems that are severe or will not go away. serious allergic reactions. Stop using Wegovy® and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeat change in vision in people with type 2 diabetes. Tell your healthcare provider if you have changes in vision during treatment with Wegovy® increased heart rate. Wegovy® can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutes depression or thoughts of suicide. You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry you food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). Wegovy® may increase the chance of food getting into your lungs during surgery or other procedures. Tell all your healthcare providers that you are taking Wegovy® before you are scheduled to have surgery or other procedures The most common side effects of Wegovy® may include: nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat. Please see Medication Guide and Prescribing Information, including Boxed Warning, for Wegovy® at About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@ Ambre James-Brown (Global)+45 3079 9289Globalmedia@ Investors:Frederik Taylor Pitter (US) +1 609 613 0568fptr@ Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@ Sina Meyer (Global) +45 3079 6656 azey@ Ida Schaap Melvold (Global) +45 3077 5649 idmg@ Max Ung (Global)+45 3077 6414mxun@ References: 1. Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69. 2. Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723. 3. Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203. 4. Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: 5. World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: 6. Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: 7. Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: 8. Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: View original content to download multimedia: SOURCE NOVO NORDISK INC. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
